CovalentInDB

CovalentInDB provides a curated database of covalent inhibitors, integrating structural, experimental bioactivity, reactive warhead, protein target, and covalent reaction mechanism information to support research and development of covalent drugs.

Key Features:

• Repository composition: Contains 4,511 covalent inhibitors, including 68 approved drugs, covering 57 distinct reactive warheads across 280 protein targets.
• Structural data: Includes crystal structures for select protein–inhibitor complexes that reveal binding-site interactions.
• Annotation of inhibitor properties: Each entry is annotated with inhibitor structure, type of reactive warhead, experimental bioactivity data, and physicochemical properties.
• Covalent reaction mechanisms: Provides documented covalent reaction mechanisms for inhibitor–target pairs along with corresponding experimental verification methods.
• Datasets for computational research: Supplies high-quality datasets suitable for evaluating and developing computational methodologies in covalent drug design.

Scientific Applications:

• Covalent drug discovery and optimization: Enables identification and optimization of covalent inhibitors against specific protein targets using integrated experimental and structural data.
• Structure-based design and interaction analysis: Supports analysis of inhibitor–protein interactions using available crystal structures to inform design decisions.
• Mechanistic studies: Facilitates investigation of covalent reaction mechanisms and validation approaches for inhibitor–target chemistry.
• Computational method development and benchmarking: Provides benchmark datasets for developing and evaluating computational approaches to covalent ligand design.
• Medicinal chemistry and pharmacology research: Serves as a reference for medicinal chemists and pharmacologists studying covalent inhibitor properties and activities.

Methodology:

Integration of scattered experimental data into a structured database with annotation of inhibitor structures, reactive warheads, experimental bioactivity and physicochemical properties, inclusion of crystal structures of inhibitor–protein complexes, and documentation of covalent reaction mechanisms with associated experimental verification methods.